Parenteral Formulation
On this page
Direct answer
Parenteral formulations bypass the gastrointestinal tract and its defences, so they must reproduce physiological tolerance themselves: sterile, pyrogen-free, and as near the tonicity and pH the tissue accepts as the drug allows. Water for Injection is the standard vehicle; solubility problems are solved by pH adjustment, cosolvents (propylene glycol, ethanol, PEG 400), cyclodextrin complexation or micellar solubilisation with surfactants like polysorbate 80. Tonicity is engineered to the freezing point depression of blood (0.52 degrees Celsius) using the sodium chloride equivalent method, and pH is held typically between 4 and 8 with minimal buffer capacity. Additives follow function — preservatives such as phenol 0.5 per cent or benzyl alcohol 1-2 per cent for multidose vials only, antioxidants, chelators — under the iron rule that single-dose large-volume injections carry none. Packaging ranges from Type I borosilicate glass ampoules to polymer bags, and particulate matter is limited pharmacopoeially per container by size band.
What you must remember
- Non-negotiables: sterility, freedom from pyrogens, tonicity near 0.9 per cent NaCl equivalence, acceptable pH, minimal particulates — the four-part definition of a quality injection.
- Tonicity arithmetic: blood freezes 0.52 degrees below water; the E value converts drug mass to NaCl-equivalent mass, and the remainder to 0.9 per cent is added as NaCl or dextrose.
- Solubilisation ladder: pH adjustment, cosolvents (propylene glycol, ethanol, PEG 400), surfactant micelles, cyclodextrins — in that order of attempt, because each adds toxicity risk.
- Preservative rules: phenol 0.5 per cent, benzyl alcohol 1-2 per cent, chlorobutol 0.5 per cent, parabens — multidose small-volume products only; never in large-volume injections, never intrathecal, never neonatal (benzyl alcohol gasping syndrome).
- Antioxidant and chelator pair: sodium metabisulphite around 0.1 per cent with disodium edetate about 0.01-0.1 per cent protects oxidation-prone drugs such as adrenaline formulations.
- Containers: Type I borosilicate glass for most injectables, Type II surface-treated glass, butyl elastomer closures, and polyolefin bags; 0.22 micrometre filters provide sterilising filtration for heat-labile solutions.
- Particulate limits (per pharmacopoeial convention): for small-volume injections, 6,000 particles of 10 micrometre and larger and 600 of 25 micrometre and larger per container; large-volume products are limited per millilitre.
- Sterilisation choice: terminal moist heat where stability allows; otherwise validated sterile filtration with aseptic filling into pre-sterilised containers.
Formulating a heat-labile injectable
Consider a poorly soluble, oxidation-prone drug for intravenous use. Solubility first: the weak acid dissolves at pH 8 but venous tolerance caps pH near 8-9, so a low-capacity phosphate buffer holds pH 7-8 — strong buffering would overwhelm the blood's own. If solubility still fails, 40 per cent propylene glycol enters the vehicle — and tonicity must then be recalculated, since the cosolvent itself contributes tonicity, checked back to 0.9 per cent equivalence by the sodium chloride equivalent method. Oxidation next: the vial is filled under nitrogen, with sodium metabisulphite and a trace of edetate to chelate metal catalysts.
The heat question decides the process: 10 per cent degradation after autoclave cycles sends the solution through a validated 0.22 micrometre filter into aseptic filling of Type I vials with extracted, autoclaved closures. Because market demand is multidose, benzyl alcohol 1 per cent is justified — but the label must exclude neonates. QC applies the parenteral checklist: assay, related substances, LAL endotoxins, particulates, extractable volume, sterility. Every excipient choice was a trade-off, and vivas reward narrating the trade-offs.
Where the exam sets its traps
Preservative prohibitions are the richest trap: candidates correctly list benzyl alcohol and then propose it for an intrathecal injection or a paediatric multidose product — both unacceptable, the first because the central nervous system tolerates preservatives poorly and the second because neonatal benzyl alcohol exposure causes the gasping syndrome. Second, the tonicity calculation: given drug mass and E value, the error is forgetting to subtract the drug's NaCl equivalence from 0.009 grams per millilitre before topping up with saline. Third, WFI versus Sodium Chloride Injection as vehicle: WFI is the compendial solvent, while saline is itself a finished product. Finally, a solution for sterile filtration must be filtered before filling, not after, because the filter is the last sterilising step the solution ever sees.
Frequently asked questions
How is isotonicity calculated by the sodium chloride equivalent method?
Convert drug mass to NaCl equivalent using the E value, subtract from the 0.9 per cent needed for the volume, add the difference as NaCl or dextrose.
Why are preservatives prohibited in single-dose large-volume injections?
The volumes infused are too large for safe preservative intake, and repeated entry is not expected; preservatives are reserved for small-volume multidose containers with validated antimicrobial effectiveness.
What solubilisation options exist for poorly soluble injectable drugs?
Adjust pH toward the ionised form, add cosolvents like propylene glycol or PEG 400, form micelles with surfactants, or complex the drug with cyclodextrins — each adding its own toxicity consideration.
What are the particulate matter limits for injections?
By common convention, small-volume injections allow up to 6,000 particles at 10 micrometre and 600 at 25 micrometre per container, counted by light obscuration.
When can a parenteral solution not be terminally sterilised?
When heat degrades drug or container; the solution passes a validated 0.22 micrometre sterilising filter and is filled aseptically, with integrity and bacterial retention studies on file.